Already available in the oral solution form, which can be stored in the refrigerator or, exceptionally, at room temperature for up to 5 days, risdiplam (Evrysdi) has now also been authorised at European level in a new galenic form:
- Roche has announced that the European Commission has authorised 5 mg tablets,
- for patients with proximal spinal muscular atrophy (SMA) aged over two years, weighing more than 20 kg and able to swallow without a feeding tube.
- a study has shown that the two forms of the drug are bioequivalent.
It is now up to the health authorities in each country to examine the reimbursement price of risdiplam tablets before they can be made available to patients.risdiplam tablets authorised at European level
